IQVIA (NYSE:IQV) Bets on AI to Power Clinical Research
IQVIA (NYSE:IQV) is focusing on AI, real-world data, and technology solutions to power clinical research, navigating a mixed demand environment influenced by biopharma funding and rising interest rates. The company's outlook is closely tied to clinical trial bookings and disciplined capital management amidst a changing landscape for life science tools and diagnostics. Operational delivery, rather than short-term market fluctuations, is seen as crucial for its long-term performance.
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
AbbVie and Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial, showing that epcoritamab combined with R-CHOP significantly improved progression-free survival in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients. The trial demonstrated a 51% reduction in the risk of disease progression or death, suggesting epcoritamab plus R-CHOP could become a new standard of care. This marks the first Phase 3 study of a bispecific antibody combination to achieve such a result in this patient population, prompting the companies to engage global regulatory authorities for next steps.
Gilead Sciences, Inc. (GILD) latest stock news and headlines
This article provides a compilation of recent news and headlines concerning Gilead Sciences, Inc. (GILD), detailing stock performance and related industry news. It covers appointments, research collaborations, market performance analysis, and broader pharmaceutical market forecasts involving CAR T-Cell therapy and small molecule drug discovery. The report also highlights Gilead's year-to-date, one-year, and three-year total returns compared to the S&P 500.
12,110 Gilead Sciences, Inc. $GILD Shares Sold by CapWealth Advisors LLC
CapWealth Advisors LLC has reduced its stake in Gilead Sciences, Inc. by 5.2%, selling 12,110 shares but still retaining 221,671 shares valued at $33.0 million. Despite this sale and recent insider selling totaling $14.9 million, analyst sentiment remains a "Moderate Buy" with an average price target of $158.78. Gilead Sciences reported strong quarterly revenue of $7.8 billion, exceeding estimates, and continues to pay a quarterly dividend of $0.82 per share.
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
NanoViricides, Inc. is providing additional details on its Phase II clinical trial for NV-387 Oral Gummies as a treatment for the Bundibugyo Ebolavirus (BDBV) outbreak in the Democratic Republic of Congo. The trial, which began enrollment for Phase IIA around September 23, 2026, aims to determine the optimal dosage regimen for NV-387, an oral antiviral designed to reduce viral load by mimicking a host-side feature viruses cannot escape. The ongoing Ebola outbreak has expanded, with over 4,000 deaths and 8,300 confirmed cases, making it the fastest-rising Ebola outbreak globally.
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
Gilead Sciences announced an expansion of its royalty-free voluntary licensing agreements for lenacapavir to include the investigational once-yearly formulation for HIV prevention. These agreements cover 120 high-incidence countries and aim to accelerate manufacturing, technology transfer, and supply planning while the Phase 3 PURPOSE 365 trial is ongoing. The initiative is part of Gilead's strategy to provide broad and sustainable access to long-acting HIV prevention options, particularly in resource-limited settings.
Assembly Biosciences Announces Two Phase 1a ABI-6250 Posters to Be Presented at The Liver Meeting 2026
Assembly Biosciences announced that two posters detailing new Phase 1a data for its investigational drug ABI-6250 will be presented at The Liver Meeting® 2026 in November. The findings indicate that ABI-6250 is well tolerated with no serious adverse events and shows effective target engagement, earning one presentation a "Poster of Distinction." The company plans to proceed into Phase 2 studies targeting chronic hepatitis delta virus infection and cholestatic liver diseases, such as primary biliary cholangitis and primary sclerosing cholangitis.
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
Nurix Therapeutics announced a second two-year extension of its research term with Gilead Sciences for an undisclosed oncology program, part of their ongoing strategic collaboration established in 2019. This extension highlights the productivity of their partnership and the potential of Nurix's targeted protein degradation platform. Nurix will receive a $10 million extension fee and retains options for co-development and profit sharing on up to two programs in the United States, in addition to potential milestone payments and royalties.
Ebola has killed 4,018 people in Congo. A trial is finding a tolerable dose for an oral drug.
NanoViricides (NNVC) is conducting a two-part Phase II trial for its oral Ebola drug, NV-387 Oral Gummies, in the Democratic Republic of Congo, where the Ebola outbreak has killed over 4,000 people. The initial Phase IIA focuses on identifying a tolerable dosing regimen before moving to a randomized, controlled Phase IIB to evaluate the drug's effectiveness. The company believes NV-387, a broad-spectrum antiviral, has the potential to be a game-changer against the current Bundibugyo Ebolavirus strain and other filoviruses, especially given the limitations of existing treatments and vaccines.
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
NanoViricides, Inc. is proceeding with its Phase II clinical trial of NV-387 Oral Gummies as a treatment for the Bundibugyo Ebolavirus (BDBV) outbreak in the Democratic Republic of Congo. The trial, designed in two parts (IIA and IIB), aims to determine a tolerable dosage regimen and then evaluate the drug's efficacy. The BDBV outbreak has intensified, particularly in Nord Kivu, with over 4,000 deaths and 8,300 confirmed cases, highlighting the urgent need for effective, easily deployable treatments like oral NV-387.
NC State honors Agilent’s Joydeep Ganguly for professional achievement
North Carolina State University’s Poole College of Management has honored Joydeep Ganguly, an NC State MBA graduate and Chief Operations and Quality Officer at Agilent Technologies, with its Professional Achievement Award. Ganguly was recognized for his global manufacturing innovation and operational leadership, overseeing a $7B+ revenue enterprise with 23+ manufacturing sites and serving customers across 110 countries. He also contributes to social impact through past board roles at the Gilead and Biogen Foundations and remains engaged with NC State by serving on its Operations and Technology Program Advisory Council.
Six new hires receive options to buy 157,500 Invivyd shares
Invivyd, Inc. (Nasdaq: IVVD) granted six new non-executive employees options to purchase an aggregate of 157,500 shares of its common stock as an inducement to employment. These options, granted on October 1, 2026, have an exercise price of $0.8165 per share, matching the closing price on the grant date. They will vest over four years, with 25% vesting on the first anniversary of the start date and the remainder in equal monthly installments, subject to continuous service.
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
Nurix Therapeutics announced a second two-year extension of its research term with Gilead Sciences for an undisclosed oncology program, building on their 2019 collaboration. This extension highlights the potential of Nurix's targeted protein degradation platform and their productive partnership, which has already advanced one drug candidate, GS-6791, into clinical development. Nurix will receive a $10 million extension fee and retains significant profit-sharing options for up to two programs in the U.S.
Gilead's second cancer research extension brings Nurix a $10 million fee.
Nurix Therapeutics announced a second two-year extension of its oncology research collaboration with Gilead Sciences, bringing Nurix a $10 million fee. The agreement allows Nurix to retain options for 50/50 U.S. profit and loss sharing on up to two programs, subject to restrictions, and makes Nurix eligible for up to approximately $1.3 billion in total payments based on milestones and tiered sales royalties. The collaboration has already advanced GS-6791 (NX-0479) into Phase 1 clinical development.
Zacks cuts Gilead earnings estimate to USD 2.14 for Gilead Sciences stock
Zacks Research has lowered its first-quarter 2028 earnings-per-share estimate for Gilead Sciences to USD 2.14, while maintaining a Hold rating. This modest adjustment comes despite Gilead reporting strong second-quarter 2026 revenues of USD 7.80 billion, surpassing consensus estimates. The company's guidance for 2026 product sales emphasizes the importance of execution outside its core HIV business as it continues to develop a diverse pipeline.
Zacks Research Lowers Earnings Estimates for Gilead Sciences
Zacks Research has lowered its Q1 2028 earnings per share estimate for Gilead Sciences from $2.15 to $2.14, while maintaining a "Hold" rating on the stock. Despite this slight reduction, the overall analyst sentiment remains positive, with 23 analysts rating Gilead a "Buy" and six a "Hold," resulting in a consensus "Moderate Buy" rating and an average price target of $158.78. The company recently reported strong quarterly revenue growth of 10.6% year-over-year to $7.8 billion, primarily driven by its HIV portfolio, and continues to pay a quarterly dividend of $0.82 per share.
Werewolf Therapeutics Inc (HOWL) Stock Price, Quote, News & History
This article provides comprehensive information on Werewolf Therapeutics Inc. (HOWL), including its stock price, key statistics, recent news, financial data, and analyst ratings. It highlights the company's biopharmaceutical focus and its recent merger with Ambros Therapeutics.
B.Riley keeps Buy rating for Kymera Therapeutics stock
B.Riley has reiterated a Buy rating and a $155.00 price target for Kymera Therapeutics (KYMR) stock following new data on its oral STAT6 degrader KT-621. The valuation is largely dependent on the results of the BROADEN2 Phase 2b study, expected by late 2026, which needs to show comparable skin clearance to existing treatments with improved itch outcomes. Kymera reported a significant revenue increase in Q2 2026 to $65.00 million, primarily from collaboration agreements, and holds $1.50 billion in cash, projected to fund operations through 2029.
31,384 Gilead Sciences, Inc. $GILD Shares Sold by CX Institutional
CX Institutional significantly reduced its stake in Gilead Sciences (NASDAQ:GILD) by 53.8% in the third quarter, selling 31,384 shares and retaining 26,913 shares valued at $4.01 million. Despite this institutional selling, other large investors have increased their positions in Gilead, while analyst ratings are mixed, with a consensus of "Moderate Buy." The article also notes recent insider sales and highlights the company's strong revenue growth driven by its HIV portfolio, particularly Biktarvy.
Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Stock
Gilead Sciences CEO Daniel O'Day recently sold 15,000 shares of company stock for $2.22 million, part of a pre-arranged trading plan. Despite this insider sale and a slight dip in share price, the company reported strong quarterly revenue of $7.8 billion, exceeding expectations. Analysts maintain a "Moderate Buy" rating with an average price target of $158.78 for GILD.
'Funny little arm': Gilead worker alleges leaders mocked disability, stalled career
A Gilead Sciences employee has filed a federal lawsuit alleging that senior leaders mocked his disability, Erb's palsy, and subsequently stalled his career. The lawsuit claims that derogatory remarks were made about his physical appearance and disability, particularly after a praised presentation, and that his complaints led to marginalization and denied advancement opportunities. The worker, who is Black, is seeking lost wages, damages, and a court order for promotion, with the case highlighting how internal discussions and deposition testimony from unrelated litigation can bring such claims to light.
Under a prearranged trading plan, Gilead Sciences (GILD) CEO sells 15,000 shares.
Gilead Sciences (GILD) Chairman & CEO, Daniel Patrick O'Day, sold a total of 15,000 shares of common stock in two transactions on October 1, 2026. The sales, totaling approximately $2.22 million, were executed under a prearranged Rule 10b5-1 trading plan adopted on February 25, 2026. After these transactions, O'Day's direct holdings in common stock stand at 566,683 shares.
Zacks cuts Gilead Sciences stock to Hold rating
Zacks Investment Research has downgraded Gilead Sciences (GILD) stock from "strong buy" to "hold" despite the company reporting strong quarterly revenue of $7.80 billion, exceeding expectations. The downgrade is attributed to mixed earnings performance, including acquisition-related costs, even as the company raised its full-year 2026 total product sales guidance to between $30.10 billion and $30.40 billion, driven by strong HIV product sales. The stock's current trading price of EUR 131.25 reflects a slight dip from its prior close, remaining below its 52-week high, with the next earnings report expected on October 28, 2026.
Confluence Investment Management LLC Cuts Position in Gilead Sciences, Inc. $GILD
Confluence Investment Management LLC reduced its stake in Gilead Sciences, Inc. by 5% in the third quarter, now holding 791,297 shares valued at $117.9 million. Despite this, analysts maintain a "Moderate Buy" consensus for GILD with an average price target of $158.78, supported by the company's Q3 revenue of $7.8 billion, which exceeded expectations. The biopharmaceutical company also recently announced a quarterly dividend of $0.82 per share.
Vir Biotechnology Appoints Aziz Sawaf as EVP and CFO
Vir Biotechnology has appointed Aziz Sawaf as Executive Vice President and Chief Financial Officer. Sawaf brings over 20 years of biopharmaceutical experience from both large and small companies, including Theravance Biopharma and Gilead Sciences. In his new role, he will oversee finance, IT, and investor relations, focusing on disciplined capital allocation and advancing the company's pipeline.
Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
Vir Biotechnology, Inc. announced the appointment of Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026. Sawaf will oversee finance, IT, and investor relations, bringing over 20 years of biopharmaceutical experience from companies like Theravance Biopharma and Gilead Sciences. The company expects his expertise in financial performance and capital allocation to be valuable as it advances its cancer immunotherapy pipeline and hepatitis delta virus program.
Gilead Sciences, Inc. (GILD) stock price, news, quote and history
This article provides a comprehensive overview of Gilead Sciences, Inc. (GILD) stock, including its current price, recent news headlines, and performance data. It highlights the stock's trading activity, various news articles discussing its trends and comparisons with other healthcare stocks, and its trailing total returns against the S&P 500. The data indicates strong performance for GILD across different timeframes.
Gilead expands lenacapavir licenses: Gilead Sciences stock has 6.53 percent upside
Gilead Sciences has expanded its lenacapavir access strategy, covering 120 high-incidence countries with royalty-free licensing agreements for the investigational once-yearly HIV prevention drug. The company's stock shows a 6.53 percent upside based on analyst targets, despite the drug still being in an investigational phase. Gilead also reported strong second-quarter revenues that beat consensus estimates, supporting a positive outlook for the company.
Immunome gains FDA IND clearance for IM‑1340 solid tumour study
Immunome Inc. (NASDAQ: IMNM) has received FDA IND clearance for its experimental cancer drug IM-1340, allowing it to proceed with a Phase 1 human study in the fourth quarter of 2026 for advanced solid tumors. This antibody-drug conjugate (ADC) targets a transport receptor expressed in various tumors and is the company's fifth program in clinical development. Immunome, a targeted oncology developer, reported cash and equivalents of US$520 million as of June 30, 2026, projected to fund operations into 2028.
Is Amgen (AMGN) Undervalued Following Its Phase 3 Sjögren's Disease Trial Update?
Amgen (AMGN) has reported positive Phase 3 trial data for dazodalibep in Sjögren's disease, leading to a significant increase in its share price. Despite this, some analyses suggest the stock is overvalued due to challenges in the obesity market, regulatory hurdles, and erosion of legacy drug sales. Conversely, Simply Wall St's DCF model indicates Amgen might be undervalued based on future cash flow estimates, highlighting a split in expert opinion regarding the company's true worth.
Gilead Sciences (GILD) Tests Its Multi Platform Story On Questions Around Valuation
Gilead Sciences (GILD) is testing its multi-platform strategy amidst valuation questions, despite recent stock gains and a federal grant for flavivirus research. While one narrative suggests GILD is 17.8% overvalued at $128.38, another DCF model indicates a 51.1% discount with a fair value of $309.33, highlighting conflicting views on its future cash flows. The company is transitioning from an HIV-focused entity to a broader biopharma with new growth drivers and potential upsides.
AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug
AstraZeneca is making a $2 billion equity investment in Summit Therapeutics, signaling a research collaboration focused on combining drugs for gastrointestinal cancers. The deal highlights AstraZeneca's interest in ivonescimab, Summit's bispecific antibody, and its potential in combination with AstraZeneca's own antibody-drug conjugates (ADCs) to overcome drug resistance in cancer treatment. This collaboration underscores a growing trend in the pharmaceutical industry to explore novel drug pairings for enhanced oncology outcomes.
Pfizer will pay Nurix another $7 million, bringing its total receipts to $82 million.
Nurix Therapeutics has achieved a $7 million research milestone under its strategic collaboration with Pfizer for the development of degrader antibody conjugates (DACs). This payment increases Nurix's total receipts from the agreement to $82 million. The collaboration, which began in September 2023 with Seagen (now Pfizer), could lead to up to $3.4 billion in additional milestone payments and tiered royalties on future product sales.
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
Nurix Therapeutics announced the achievement of a $7 million research milestone under its strategic collaboration with Pfizer for the discovery and development of degrader antibody conjugates (DACs). This payment brings the total received under the agreement to $82 million. The collaboration, initially with Seagen Inc. (now Pfizer), could yield up to $3.4 billion in milestone payments and royalties.
Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough (NYSE:PFE)
Pfizer is recommended as a Buy due to its strong growth portfolio and significant cost-restructuring initiatives, despite near-term challenges from COVID-19 revenue normalization and patent expirations. The company's new and acquired products are driving double-digit growth, while planned savings of $9.7 billion by 2029 are expected to bolster earnings and margins. A 6% dividend yield and deep-value multiple provide investor support for medium- to long-term upside.
Abbott Laboratories (ABT) stock price, news, quote and history
This page provides an overview of Abbott Laboratories (ABT) stock, including its current price, recent news headlines, dividend information, and performance metrics. As of September 29, 2026, ABT was trading at 100.95 USD, with a slight dip after hours, and had announced a cash dividend of $0.63. The news section highlights recent analyst opinions and company-specific events affecting ABT and related healthcare stocks.
PERCEPTIVE ADVISORS LLC Adds Nurix Therapeutics Inc (NRIX) -- Shares Look 197% Overvalued on GF Value
PERCEPTIVE ADVISORS LLC has increased its stake in Nurix Therapeutics Inc (NRIX) by acquiring 1,216,207 additional shares, making it a significant allocation in their healthcare-focused portfolio. Despite the firm's conviction in the clinical-stage biopharmaceutical company's pipeline, Nurix Therapeutics is classified as "Significantly Overvalued" by GuruFocus, trading at roughly 197% above its intrinsic value. The company exhibits strong growth potential but struggles with profitability, reflected in negative ROE and ROA, alongside a low Piotroski F-Score.
Can Lenacapavir Power Gilead Sciences (GILD)’s Next Growth Phase?
Gilead Sciences is expanding its royalty-free licensing for lenacapavir to global markets, including an investigational once-yearly formulation for HIV PrEP, aiming for early market dominance and strengthening its core HIV franchise. While the company saw strong HIV product sales growth, significant acquisition-related R&D charges and declines in Veklury and cell therapy sales have led to recent GAAP losses and reduced cash reserves. Despite these headwinds, sustained HIV and oncology revenue growth, coupled with robust operating cash flow, positions Gilead to capitalize on its pipeline and new PrEP initiatives.
Gilead Sciences stock last trades at USD 152.43 on September 28, 2026
Gilead Sciences stock closed at USD 152.43 on September 28, 2026, marking a 0.99% increase from its previous close. The company recently expanded its royalty-free voluntary licensing agreements for investigational once-yearly lenacapavir for HIV prevention to 120 high-incidence countries. Additionally, Gilead and the Pan American Health Organization established a regional pathway for access to twice-yearly lenacapavir for HIV prevention in Latin America and the Caribbean.
Can AbbVie’s Backing Help ADARx Win Over Biotech IPO Investors at a $1.74 Billion Valuation?
ADARx Pharmaceuticals is seeking to raise up to $371.9 million in a U.S. IPO, targeting a valuation of up to $1.74 billion, with significant backing from AbbVie Inc. AbbVie has agreed to invest up to $100 million in a concurrent private placement, giving it a 4.9% stake, and previously collaborated with ADARx with a $335 million payment. While ADARx has multiple programs, including a late-stage candidate onvuzosiran, the IPO's success hinges on investors' willingness to value experimental medicines given the selective biotech IPO market.
Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing?
This article compares the growth stories of Gilead Sciences (GILD) and Danaher Corporation (DHR), both prominent healthcare companies. Gilead shows current momentum driven by its double-digit HIV business growth, while Danaher is in an earlier stage of recovery with improving life-sciences market spending, despite some project timing issues. Ultimately, Gilead's growth is more immediately apparent in its results, whereas Danaher's potential relies on future translation of current orders and market improvements into reported growth.
AbbVie Won FDA Approval for Parkinson’s Pill Juvmo. Here’s Why Management Already Expects a Slow Start
AbbVie recently received FDA approval for its new Parkinson's pill, Juvmo (tavapadon), which is expected to be available to U.S. patients in October 2026. Despite this approval, management anticipates a slow start for the drug due to missing the Medicare reimbursement window for 2027. AbbVie projects its Parkinson's franchise to reach $5 billion in peak sales, driven by Juvmo and other therapies like Vyalev.
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
Xilio Therapeutics has appointed Dr. Yariv J. Houvras as its new Chief Medical Officer, bringing over two decades of experience in clinical development and immuno-oncology. Dr. Houvras will be instrumental in advancing Xilio's pipeline of masked immuno-oncology therapies, including XTX501, a bispecific PD-1 / masked IL-2. His expertise will support the company's goal of developing tumor-selective treatments for cancer.
Xilio Therapeutics Names Yariv Houvras Chief Medical Officer as Immuno-Oncology Pipeline Advances
Xilio Therapeutics has appointed Yariv J. Houvras, M.D., Ph.D., as chief medical officer to advance its masked immuno-oncology pipeline. Houvras brings over 20 years of experience in clinical development, translational medicine, and immuno-oncology, including work on bispecific therapies and antibody-drug conjugates. His primary focus will be on the clinical development of XTX501, a bispecific PD-1/masked IL-2 program, as the company seeks to develop tumor-selective therapies.
Xilio Therapeutics appoints Yariv Houvras as chief medical officer
Xilio Therapeutics has appointed Dr. Yariv Houvras as its new chief medical officer. Dr. Houvras brings over 20 years of experience in clinical development, translational medicine, and immuno-oncology, and will oversee the company's clinical development, including its bispecific PD-1/masked IL-2 therapy, XTX501, and its pipeline of multi-specific masked T cell engagers. His previous roles include leadership positions at Tubulis, GmbH and Regeneron Pharmaceuticals, Inc.
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
Xilio Therapeutics has appointed Dr. Yariv Houvras as its new Chief Medical Officer. Dr. Houvras brings over two decades of experience in clinical development and immuno-oncology, previously serving at Tubulis and Regeneron Pharmaceuticals. His expertise is expected to be invaluable as Xilio advances its masked immuno-oncology therapies, including XTX501, for cancer treatment.
Gilead Sciences (GILD) Share Price, News, Stock Market Cap NASDAQ
This article provides detailed stock market information for Gilead Sciences (GILD) on NASDAQ. It includes the current share price, trading activity, market capitalization, and various financial metrics such as trading range and volume. The content also offers a company profile and frequently asked questions about Gilead Sciences.
Insmed (INSM) Could Be 40% Undervalued On FDA Priority Review News
Insmed (INSM) has received FDA Priority Review for its supplemental New Drug Application for ARIKAYCE, leading to speculation that the stock is 40% undervalued despite recent short-term share price drops. The company's fair value is estimated at $197.14 against a current close of $117.83, driven by a strong pipeline and upcoming catalysts like the U.S. launch of brensocatib. However, the article also notes a high P/S ratio, suggesting investors are already paying a premium based on future earnings potential.
Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
This article compares Gilead Sciences (GILD) and Abbott Laboratories (ABT) as dividend healthcare stocks, highlighting their differing risk-reward profiles. Gilead offers stronger current growth, particularly in its HIV franchise, but carries concentration risk and high R&D spending for diversification. Abbott, while growing slower, boasts a more diversified business across medical devices, diagnostics, and nutrition, along with a long history of consistent dividend increases.
Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification?
This article compares Gilead Sciences, Inc. (NASDAQ: GILD) and Johnson & Johnson (NYSE: JNJ), evaluating whether Gilead's faster growth, driven by its HIV franchise, is more appealing than J&J's broader diversification across pharmaceuticals and MedTech. While Gilead shows stronger underlying growth and raised its outlook, it also carries concentration risk due to its reliance on HIV sales. J&J, despite challenges like Stelara's decline, demonstrated the value of diversification by still raising its guidance, offering a more balanced investment case.
